Amarin reported $0 in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amarin USD 0 0 Mar/2025
AstraZeneca USD 32.24B 1.68B Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
DBV Technologies USD 6.1M 2.49M Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026